AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12801313
Drug: montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: montelukast 10 mg/desloratadine 5 mg combination
Trial: 12801313
Drug: montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: montelukast 10 mg alone
Trial: 8852914
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir therapy (300 mg/m2/dose, administered either twice daily or three times per day for 6 months)
Trial: 8852914
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir therapy
Trial: 1497125
Drug: Fentanyl (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (5 micrograms/kg bolus, 2 micrograms kg‐1 h‐1 infusion)
Trial: 1497125
Drug: Pentazocine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (2 mg/kg bolus, 0.8 mg kg‐1 h‐1 infusion)
Trial: 1497125
Drug: Ketamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (2 mg/kg bolus, 0.8 mg kg‐1 h‐1 infusion)
Trial: 6140128
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tiapride 3-times daily for 14 days
Trial: 6140128
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg glafenine 3-times daily for 14 days
Trial: 22433921
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole (RPZ) 20 mg b.i.d.
Trial: 22433921
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole (RPZ) 10 mg b.i.d.
Trial: 22433921
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole (RPZ) 20 mg q.d. (control)
Trial: 19505390
Drug: Nebulized flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized flunisolide (40 microg/kg twice daily for 7 days, then 20 microg/kg twice daily for 14 days)
Trial: 19505390
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (0.5 mg twice daily for 7 days, then 0.25 mg twice daily for 15 days)
Trial: 11682426
Drug: Gel-pad
RxNorm normalized name: SCARCARE Gel-Pad Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-pad
Trial: 11682426
Drug: 1000-mL lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000-mL lactated Ringer's bag
Trial: 12748510
Drug: Docosahexaenoic acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid supplementation (approximately 200 mg/d)
Trial: 10807815
Drug: MDI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI with Nebuchamber (placebo MDI through NESD, four puffs) and salbutamol 0.5 mL (2.5 mg) as NWA (group I, n = 19)
Trial: 10807815
Drug: Salbutamol MDI
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol MDI and 0.5 mL of saline solution (group II, n = 23)
Trial: 8117556
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with mucopolysaccharide polysulphate/salicylic acid cream
Trial: 30607719
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) 300 J per thigh
Trial: 28694341
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with functional bracing
Trial: 19808491
Drug: Radiofrequency catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency catheter ablation (RFA) with/without antiarrhythmic drug (AAD)
Trial: 19808491
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug (AAD) alone
Trial: 9891194
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (CH) alone (70 mg/kg)
Trial: 9891194
Drug: Chloral hydrate/hydroxyzine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate/hydroxyzine (CH/H) (70 mg/kg CH + 2 mg/kg hydroxyzine)
Trial: 8015507
Drug: 2 mg/24
RxNorm normalized name: testosterone 2 mg/24 hr transdermal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/24 h administration of oestradiol valerate
Trial: 8015507
Drug: 1.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/day of percutaneous 17 beta-oestradiol
Trial: 8015507
Drug: 0.05 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/day of transdermic oestradiol
Trial: 2660632
Drug: Clemastine syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine syrup
Trial: 354474
Drug: 265 mg
RxNorm normalized name: doconexent 265 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 265 mg theophylline (150 mg slow-release)
Trial: 354474
Drug: 265 mg
RxNorm normalized name: doconexent 265 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 265 mg theophylline + 7.5 mg hydroxyzine hydrochloride
Trial: 31830776
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus probiotics (group B)
Trial: 31830776
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus sulforaphane (group C)
Trial: 31830776
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy only (group A)
Trial: 28443690
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of vaginal micronised progesterone tablets (Group A)
Trial: 25818061
Drug: Bupropion, sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion, sustained-release 150 mg, twice daily
Trial: 23963057
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) 0.5-1.8 mg/kg per day
Trial: 23963057
Drug: Other early
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other early standard therapy (OEST, mainly methylphenidate)
Trial: 20946437
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg bi-hourly for 3 nights)
Trial: 20946437
Drug: Placebo (indistinguishable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (indistinguishable gum bi-hourly for 3 nights)
Trial: 17920770
Drug: First-line treatments
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatments including certain antidepressants (tricyclic antidepressants and dual reuptake inhibitors of both serotonin and norepinephrine)
Trial: 17920770
Drug: Opioid analgesics
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid analgesics and tramadol
Trial: 17920770
Drug: Certain antiepileptic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Certain antiepileptic and antidepressant medications, mexiletine, N-methyl-D-aspartate receptor antagonists, and topical capsaicin
Trial: 9661537
Drug: Nurse-administered subcutaneous
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered subcutaneous morphine
Trial: 9661537
Drug: i.v. patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. patient-controlled analgesia morphine
Trial: 1146857
Drug: Directive play
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directive play therapy
Trial: 1146857
Drug: Nondirective play
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nondirective play therapy
Trial: 28342891
Drug: Group Acceptance
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Acceptance and Commitment Therapy (GACT)
Trial: 22018333
Drug: Recommended Pharmacological
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended Pharmacological Treatment (RPT)
Trial: 17203122
Drug: atracurium (priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium (priming with 0.05 mg/kg followed by 0.55 mg/kg after induction of anaesthesia)
Trial: 14679270
Drug: Efalizumab, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab, 1 mg/kg, 12 weekly doses
Trial: 9722127
Drug: oral ornidazole
RxNorm normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral ornidazole 2 x 500 mg/day for 5 days
Trial: 9722127
Drug: vaginal ornidazole
RxNorm normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal ornidazole 500 mg/day for 5 days
Trial: 9722127
Drug: oral secnidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral secnidazole 2 g in a single dose and vaginal ornidazole 500 mg/day for 5 days
Trial: 9722127
Drug: oral secnidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral secnidazole 2 g in a single dose and vaginal metronidazole 2 x 500 mg/day for 7 days
Trial: 9722127
Drug: oral ornidazole
RxNorm normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral ornidazole 2 x 500 mg/day for 5 days and vaginal metronidazole 2 x 500 mg/day for 7 days
Trial: 9722127
Drug: vaginal metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal metronidazole 2 x 500 mg/day for 7 days
Trial: 7978130
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 micrograms.ml‐1 in 0.9% sodium chloride
Trial: 7978130
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 micrograms.ml‐1 + adrenaline 2.5 micrograms.ml‐1
Trial: 7978130
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 micrograms.ml‐1 + clonidine 3 micrograms.ml‐1
Trial: 2531992
Drug: IA (Intraarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA (Intraarterial FUdR, 0.2 mg/kg/d x 14 days/month)
Trial: 2531992
Drug: IA/IV (Intraarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA/IV (Intraarterial FUdR + systemic 5‐FU 700 mg/m2/d x 3 days/month)
Trial: 31834936
Drug: Smartphone application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application providing information and support for medication abortion (MA)
Trial: 31018852
Drug: Receipt of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receipt of smoking cessation medications while hospitalized
Trial: 31018852
Drug: Discharge with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge with a prescription
Trial: 31018852
Drug: Receipt of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receipt of medication as an inpatient
Trial: 24465387
Drug: Brief psychodynamic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychodynamic interpersonal therapy (PIT)
Trial: 22436453
Drug: Selenium yeast
RxNorm normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium yeast (200 μg/day) supplementation for 3 years
Trial: 15726878
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg) + Triamterene (150 mg)
Trial: 15726878
Drug: Triamterene (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene (150 mg)
Trial: 12049800
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) low dosage (100 mg daily)
Trial: 12049800
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) medium dosage (200 mg daily)
Trial: 10090547
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled budesonide (1600 microg d(-1) for 3 d and 800 microg for 7 d)
Trial: 10090547
Drug: Oral betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral betamethasone (6, 4 and 2 mg for 3 d)
Trial: 7788149
Drug: Prednisone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (10 mg/day for first 12 weeks, tapering to 7.5 mg/day for weeks 13-14, 5 mg/day for weeks 15-16, and 2.5 mg/day for weeks 17-18)
Trial: 7788149
Drug: Prednisone (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (after tapering)
Trial: 25968407
Drug: Pravastatin 80
RxNorm normalized name: pravastatin 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 80 mg
Trial: 19138366
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of testosterone and vardenafil
Trial: 15009968
Drug: Inspiring nitric
RxNorm normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiring nitric oxide (NO) at 20±1 mg/L for 30 minutes before admission and urokinase (150x10^4 U) intravenously injected with 0.9% sodium chloride within 30 minutes
Trial: 15009968
Drug: Urokinase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase treatment as in test group
Trial: 9845708
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole (200 mg daily)
Trial: 1675705
Drug: Levamisole, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole, 2.5 mg/kg on alternate days (31 patients)
Trial: 18422579
Drug: Choreito (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choreito (7.5 g/day)
Trial: 12696391
Drug: Intervention 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention 2: Brief (5‐8 minutes) structured medical counselling for tobacco quitting, followed by reinforcement advice on 3 occasions during 3 months, accompanied by nicotine patches individualized according to nicotine dependence.
Trial: 9068017
Drug: 39 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 39 mmol/L bicarbonate-buffered CAPD solution
Trial: 9068017
Drug: 34 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 34 mmol/L bicarbonate-buffered CAPD solution
Trial: 8446394
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 10 mg/kg b.i.d. for 7 days (n = 134)
Trial: 8446394
Drug: Cefaclor 13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 13.5 mg/kg t.i.d. for 7 days (n = 136)
Trial: 3510320
Drug: Cefotaxime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (2 intravenous doses preoperatively)
Trial: 30819765
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + radiation therapy + temozolomide
Trial: 24993838
Drug: Gentamicin collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin collagen implant (GCI)
Trial: 22421244
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (amphotericin B 1 mg/kg per day and 5FC 100 mg/kg per day for 2 weeks)
Trial: 22421244
Drug: IFNγ two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNγ two doses (standard therapy plus IFNγ1b 100 μg on days 1 and 3)
Trial: 22421244
Drug: IFNγ six
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNγ six doses (standard therapy plus IFNγ1b 100 μg on days 1, 3, 5, 8, 10, and 12)
Trial: 21054874
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (exact dosage and duration not specified)
Trial: 17991308
Drug: Sublingual ET
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual ET (2 mg tablet)
Trial: 17991308
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler delivering 2052 microg of ET
Trial: 11865557
Drug: Antipyretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipyretic treatment during febrile episodes
Trial: 11865557
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam as intermittent prophylaxis
Trial: 11865557
Drug: Continuous anticonvulsant
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous anticonvulsant treatment
Trial: 3111166
Drug: 10% glucose
RxNorm normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glucose intravenous infusion
Trial: 28903957
Drug: Skewed protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skewed protein distribution (10 g at breakfast, 20 g at lunch, and 60 g at dinner; n = 20)
Trial: 28903957
Drug: Even protein
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Even protein distribution (30 g each at breakfast, lunch, and dinner; n = 21)
Trial: 21491994
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (5 μg/kg)
Trial: 21491994
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet)
Trial: 8102399
Drug: Olsalazine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine (30 mg/kg/day, max 2 g/day)
Trial: 8102399
Drug: Sulfasalazine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (60 mg/kg/day, max 4 g/day)
Trial: 2967028
Drug: acebutolol 200
RxNorm normalized name: acebutolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebutolol 200 mg
Trial: 29719884
Drug: Software-directed medication
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Software-directed medication history
Trial: 29719884
Drug: Paper-based medication
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-based medication history
Trial: 28594615
Drug: Tooth-brushing with
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth-brushing with concurrent suctioning technique
Trial: 21508856
Drug: LY2140023 monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2140023 monohydrate 5 mg twice daily
Trial: 21508856
Drug: LY2140023 monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2140023 monohydrate 20 mg twice daily
Trial: 21508856
Drug: LY2140023 monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2140023 monohydrate 40 mg twice daily
Trial: 21508856
Drug: LY2140023 monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2140023 monohydrate 80 mg twice daily
Trial: 21508856
Drug: Placebo (am)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (am) and 15 mg of olanzapine (pm) daily
Trial: 9012279
Drug: Histamine H2-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H2-receptor antagonists in conventional dosages
Trial: 9012279
Drug: Prokinetic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prokinetic agents
Trial: 3301166
Drug: Indomethacin treatment
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin treatment before feeding
Trial: 3301166
Drug: Indomethacin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (oral dose 2h before measurement)
Trial: 20598453
Drug: Combined endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined endocrine therapy and external‐beam radiotherapy
Trial: 16630091
Drug: Magnesium l-lactate
RxNorm normalized name: magnesium L-lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium l-lactate (504 mg elemental magnesium daily)
Trial: 14681282
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (12.5 mg zinc sulphate daily for 6 days a week for 6 months)
Trial: 1636921
Drug: Tramadol and
RxNorm normalized name: tramadol and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol and metamizole infusion (400 mg tramadol plus 5 g metamizole in 500 ml electrolyte solution)